Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
PDE1B
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "PDE1B" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions [1] .
Target:
Research Areas:
DSR-141562 is a novel, orally active, and selective brain-penetrant phosphodiesterase 1 (PDE1) inhibitor. DSR-141562 shows preferential selectivity for human PDE1B with an IC50 of 43.9 nM, and the IC50 values for human PDE1A and 1C are 97.6 and 431.8 nM, respectively. DSR-141562 can be used for the study of positive symptoms, negative symptoms and cognitive impairments associated with schizophrenia [1] .
Target:
Research Areas:
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders [1].
Cat. No.: HY-RS10211
Target:
Research Areas:
PDE1B Human Pre-designed siRNA Set A contains three designed siRNAs for PDE1B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17837
Target:
Research Areas:
Pde1b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde1b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Target:
Research Areas:
ITI-214 free base is a potent, CNS-active, orally bioavailable PDE1 inhibitor (Ki of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 free base inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with Kis of 33 pM, 380 pM and 35 pM, respectively. ITI-214 free base shows efficacy in various animal models of motor and cognitive functions [1] .
Cat. No.: HY-RS24305
Target:
Research Areas:
Pde1b Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde1b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-120741
CAS No.: 1798334-07-2
Target:
Research Areas:
PF-04822163 is an orally active, selective, and blood-brain barrier permeable PDE1 inhibitor with IC50 values of 2 nM, 2.4 nM, and 7 nM for PDE1A, PDE1B, and PDE1C respectively. PF-04822163 can be used in the research of attention deficit hyperactivity disorder or Parkinson's disease [1].
Cat. No.: HY-120195
CAS No.: 1628342-10-8
Target:
Research Areas:
PF-04677490 is a PDE1 inhibitor (IC50: 21 nM). PF-04677490 has IC50s of 21 nM, 83 nM, and 118 nM for PDE1B1, PDE1C, and PDE1A, respectively. PF-04677490 efficaciously inhibits cAMP- and cGMP-hydrolytic activity [1].
Cat. No.: HY-147946
CAS No.: 3031349-98-8
Research Areas:
PDE1-IN-4 (compound 2g) is a potent and selective PDE1 (phosphodiesterase-1) inhibitor, with IC50 values of 10, 145, and 354 nM for PDE1C, PDE1A, and PDE1B, respectively. PDE1-IN-4 inhibits myofibroblast differentiation of human lung fibroblasts induced by TGF-β1. PDE1-IN-4 shows anti-fibrosis effects through the regulation of cAMP (3′,5′-cyclic adenosine monophosphate) and cGMP (3′,5′-cyclic guanosine monophosphate). PDE1-IN-4 can be used for idiopathic pulmonary fibrosis (IPF) research [1].
Cat. No.: HY-120195A
CAS No.: 2230054-75-6
Target:
Research Areas:
PF-04827736 (compound (S)-3) is a selective PDE1 inhibitor with IC50 values of 9.1 nM, 38 nM and 42 nM for PDE1B, PDE1C and PDE1A. PF-04827736 selectively inhibits human PDE1 over the other 10 superfamily members (PDE2-PDE11). PF-04827736 can be used for the study of cardiovascular disease [1].
Cat. No.: HY-P75960
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; Cam-PDE 1B; PDE1B1; PDES1B
Species:
Source:
Cat. No.: HY-180803
Target:
Research Areas:
LH17, a Kaempferol (HY-14590) derivative, is a potent and selective PDE4 inhibitor (PDE4D2 IC50 = 73 nM, PDE4B2 IC50 = 190 nM). LH17 exhibits remarkable selectivity (>136-fold) against other PDE isoforms (PDE1B/2A/3A/5A/8A/9A/10A) (IC50 > 10000 nM), with the exception of PDE7A1 (IC50 = 300 nM). LH17 distinctly interacts with PDE4 M-pocket. LH17 demonstrates remarkable anti-fibrotic efficacy in both in vitro and in vivo models. LH17 can be used for idiopathic pulmonary fibrosis (IPF) research [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
